Welcome to our dedicated page for Eledon Pharmaceuticals news (Ticker: ELDN), a resource for investors and traders seeking the latest updates and insights on Eledon Pharmaceuticals stock.
Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN) is a clinical-stage biotechnology company dedicated to developing immune-modulating therapies for life-threatening conditions. The company's main focus lies in targeting the CD40L pathway, aiming to provide novel treatments for organ and cellular transplantation, autoimmune diseases, and neurodegenerative conditions.
At the core of Eledon's research is tegoprubart, a humanized IgG1 anti-CD40L antibody. Tegoprubart shows high affinity for CD40 Ligand (CD40L), a crucial biological target involved in generating pro-inflammatory responses in autoimmune diseases, transplant rejection, and neuroinflammation. The CD40/CD40L pathway is essential in both adaptive and innate immune responses, making it a prime target for non-lymphocyte depleting therapeutic interventions.
In 2023, Eledon achieved significant milestones, including presenting initial clinical evidence of tegoprubart's potential to prevent organ rejection while maintaining robust kidney function and a favorable safety profile. The company also played a pivotal role in the second-ever genetically modified heart transplant from a pig to a human, using tegoprubart as a key immunosuppressive component.
Looking forward to 2024, Eledon is committed to advancing its clinical programs. Key initiatives include ongoing development in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). The firm has several pivotal studies underway, including a Phase 1b trial for kidney transplantation, a long-term safety and efficacy extension study, and the Phase 2 BESTOW trial comparing tegoprubart to tacrolimus in kidney transplant patients.
Financially, Eledon reported a net loss of $40.3 million for 2023, slightly improved compared to the previous year's $88.0 million, which included a significant non-cash goodwill impairment charge. The firm's research and development expenses increased to $30.3 million, underscoring its commitment to advancing its clinical pipeline.
Eledon Pharmaceuticals is headquartered in Irvine, California, and continually seeks to build on its deep historical knowledge of anti-CD40L biology to develop groundbreaking therapies. For more information, visit www.eledon.com.
Eledon Pharmaceuticals (NASDAQ: ELDN) reported its Q1 2022 results, showcasing a net loss of $9.9 million ($0.69 per share), up from a loss of $8.5 million ($0.57 per share) in Q1 2021. The increase in losses was primarily due to higher R&D expenses, which totaled $6.6 million, compared to $5.7 million last year. Significant developments include the completion of patient enrollment for the Phase 2a tegoprubart study in ALS, with topline data anticipated in June 2022, and the first patient dosed in the IgA Nephropathy trial, expanding the clinical footprint internationally.
Eledon Pharmaceuticals has initiated a multicenter, open-label Phase 2a study for its drug, tegoprubart, aimed at treating patients with IgA Nephropathy (IgAN), a kidney condition affecting over 150,000 Americans. The study will assess the drug's safety and efficacy based on changes in urine protein levels over 24 weeks, with additional assessments through 96 weeks. Eledon's CEO highlighted the potential of tegoprubart to improve current treatment standards for IgAN, a disease with significant unmet medical needs.
Eledon Pharmaceuticals (NASDAQ: ELDN) will release its Q1 2022 financial results on May 12, 2022, following market close. A conference call and webcast are scheduled for 4:30 p.m. ET to discuss these results. Eledon focuses on developing treatments for organ and cell transplantation, autoimmune diseases, and neurodegenerative conditions. Their lead candidate, tegoprubart, targets the CD40 Ligand pathway and shows potential across various therapeutic areas. After the live event, the webcast will be archived on Eledon's website.
Eledon Pharmaceuticals, a clinical stage biopharmaceutical company specializing in treatments for transplant and autoimmune conditions, announced its participation in a fireside chat at the LifeSci Partners Immunology & Inflammation Symposium on May 10, 2022, at 2:00 p.m. ET. Interested individuals can register for the webcast here. A replay will later be available on the company's website.
Eledon Pharmaceuticals, a clinical stage biopharmaceutical company focused on organ transplantation and autoimmune diseases, announced that Dr. Steve Perrin will present at NobleCon18 on April 21, 2022 at 11:30 a.m. ET.
The company is advancing its lead compound, tegoprubart, targeting the CD40 Ligand pathway, used for treating transplant patients and autoimmune conditions. A replay of the presentation will be accessible on the Noble Capital Markets’ website and Channelchek.
Eledon Pharmaceuticals, a clinical stage biopharmaceutical company, announced it will host its first R&D Day on April 28, 2022, from 10 a.m. to 12 p.m. ET. This virtual event will feature Eledon’s senior management team alongside leading experts discussing the investigational drug tegoprubart and the potential of CD40 Ligand targeted immunotherapy for conditions like ALS and kidney transplantation. The presentation will include insights from prominent professionals in neurology and renal medicine. For more details, visit the company's R&D Day website.
Eledon Pharmaceuticals (NASDAQ: ELDN) reported its fourth quarter and full-year 2021 results, marking a significant year of progress.
They fully enrolled a Phase 2a trial for tegoprubart in ALS and initiated multiple other clinical studies. The cash balance stands at $84.8 million, expected to fund operations into 2024.
Net losses were $34.5 million for 2021, up from $22.8 million in 2020, primarily due to increased R&D expenses.
Topline data from the ALS trial is expected in 2Q 2022.
Eledon Pharmaceuticals (NASDAQ: ELDN) will release its fourth quarter and full year 2021 financial results on March 24, 2022, after market close. The management team will host a conference call and webcast at 4:30 p.m. ET to discuss the results. Eledon focuses on developing innovative treatments for organ and cell transplantation, autoimmune diseases, and neurodegenerative disorders. Its lead product, tegoprubart, targets the CD40 Ligand pathway, offering potential benefits for patients requiring transplants or suffering from ALS.
Eledon Pharmaceuticals (NASDAQ: ELDN) announced the completion of enrollment for all cohorts in its Phase 2a study of tegoprubart in Amyotrophic Lateral Sclerosis (ALS). The company received USAN approval for the generic name tegoprubart for its lead asset AT-1501. With a robust capital position, Eledon is well-funded to support operations into 2024. Anticipated clinical data readouts in 2022 include topline results from the ALS trial and studies in kidney transplantation and IgA nephropathy. Eledon aims to advance precision therapies targeting the CD40 ligand pathway.
Eledon Pharmaceuticals (NASDAQ: ELDN), a clinical stage biopharmaceutical company, announced that its CEO, David-Alexandre C. Gros, M.D., will participate in a fireside chat at the 11th Annual SVB Leerink Virtual Global Healthcare Conference on February 17 at 5:00 p.m. EST. This event focuses on innovative treatments for organ and cell transplantation, autoimmune diseases, and neurodegenerative conditions. Interested participants can register for the webcast here.
FAQ
What is the current stock price of Eledon Pharmaceuticals (ELDN)?
What is the market cap of Eledon Pharmaceuticals (ELDN)?
What does Eledon Pharmaceuticals specialize in?
What is tegoprubart?
What are the recent achievements of Eledon Pharmaceuticals?
What are Eledon Pharmaceuticals' financial highlights for 2023?
Where is Eledon Pharmaceuticals headquartered?
What clinical trials are currently underway at Eledon Pharmaceuticals?
How does tegoprubart work?
What is the significance of the CD40/CD40L pathway?
What are the future plans for Eledon Pharmaceuticals?
How can I learn more about Eledon Pharmaceuticals?
